BioCentury
ARTICLE | Regulation

March 5 COVID Quick Takes: Lilly mAbs clear EU hurdle; plus Adaptive authorization, Takeda pushes vaccine ahead in Japan, Aerpio therapy out of I-SPY  

March 6, 2021 1:45 AM UTC

EMA’s CHMP recommended use of bamlanivimab from  AbCellera Biologics Inc. (NASDAQ:ABCL) and  Eli Lilly and Co. (NYSE:LLY), alone and together with Lilly’s etesevimab. The committee’s opinion backs use of bamlanivimab and the combo for confirmed COVID-19 in patients aged 12 years and up that do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.

FDA authorizes Adaptive T cell test for COVID-19
Adaptive Biotechnologies Corp. (NASDAQ:ADPT) received emergency use authorization (EUA) from FDA for its T-Detect test to detect recent or prior infection with SARS-CoV-2, with the goal of identifying individuals, including Long COVID patients, who cleared the virus without forming antibodies. The TCR sequencing-based test, which was developed via a partnership with Microsoft, launched Feb. 23 as a laboratory-developed test (LDT)...